ABSTRACT
Methicillin-resistant Staphylococcus aureus bacteremia in patients in intensive care units is associated with significant morbidity and mortality. Prompt clinical attention is essential to ensure good outcomes, including identification and management of the source of infection and any associated complications. Foreign-body sources of infection should be removed or replaced in the majority of cases, and debridement of infectious foci should be undertaken. Particular attention should be given to evaluation for the presence of cardiac involvement because inadequately managed S. aureus endocarditis is life threatening. Selection of an appropriate antibiotic regimen is also an essential factor for optimal management.
KEYWORDS
Endocarditis - vancomycin - glycopeptide - daptomycin
REFERENCES
-
1
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004.
Am J Infect Control.
2004;
32
470-485
-
2
Blot S I, Vandewoude K H, Hoste E A, Colardyn F A.
Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus
.
Arch Intern Med.
2002;
162
2229-2235
-
3
Cosgrove S E, Sakoulas G, Perencevich E N, Schwaber M J, Karchmer A W, Carmeli Y.
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.
Clin Infect Dis.
2003;
36
53-59
-
4
Fowler Jr V G, Olsen M K, Corey G R et al..
Clinical identifiers of complicated Staphylococcus aureus bacteremia.
Arch Intern Med.
2003;
163
2066-2072
-
5
Malanoski G J, Samore M H, Pefanis A, Karchmer A W.
Staphylococcus aureus catheter-associated bacteremia: minimal effective therapy and unusual infectious complications associated with arterial sheath catheters.
Arch Intern Med.
1995;
155
1161-1166
-
6
Lautenschlager S, Herzog C, Zimmerli W.
Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions.
Clin Infect Dis.
1993;
16
567-573
-
7
Ringberg H, Thoren A, Lilja B.
Metastatic complications of Staphylococcus aureus septicemia. to seek is to find.
Infection.
2000;
28
132-136
-
8
Chang F Y, Peacock Jr J E, Musher D M et al..
Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.
Medicine (Baltimore).
2003;
82
333-339
-
9
Fowler Jr V G, Li J, Corey G R et al..
Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients.
J Am Coll Cardiol.
1997;
30
1072-1078
-
10
Fowler Jr V G, Sanders L L, Kong L K et al..
Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up.
Clin Infect Dis.
1999;
28
106-114
-
11
Roder B L, Wandall D A, Frimodt-Moller N, Espersen F, Skinhoj P, Rosdahl V T.
Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark.
Arch Intern Med.
1999;
159
462-469
-
12
Sullenberger A L, Avedissian L S, Kent S M.
Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia.
J Heart Valve Dis.
2005;
14
23-28
-
13
Abraham J, Mansour C, Veledar E, Khan B, Lerakis S.
Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S. aureus and methicillin-resistant S. aureus bacteremia.
Am Heart J.
2004;
147
536-539
-
14
Reynolds H R, Jagen M A, Tunick P A, Kronzon I.
Sensitivity of transthoracic versus transesophageal echocardiography for the detection of native valve vegetations in the modern era.
J Am Soc Echocardiogr.
2003;
16
67-70
-
15
Fowler Jr V G, Sanders L L, Sexton D J et al..
Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients.
Clin Infect Dis.
1998;
27
478-486
-
16
Chamis A L, Peterson G E, Cabell C H et al..
Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators.
Circulation.
2001;
104
1029-1033
-
17
Jernigan J A, Farr B M.
Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis.
Ann Intern Med.
1993;
119
304-311
-
18
Wilson R, Hamburger M.
Fifteen years' experience with Staphylococcus septicemia in a large city hospital: analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954.
Am J Med.
1957;
22
437-457
-
19
Raad I I, Sabbagh M F.
Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review.
Clin Infect Dis.
1992;
14
75-82
-
20 Boucher H, Corey G, Filler S et al.. Appropriateness of two-week therapy for catheter-related S. aureus bacteremia. Presented at the 46th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 27-30, 2006 San Francisco, CA; Abstract number L-1204
-
21
Small P M, Chambers H F.
Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.
Antimicrob Agents Chemother.
1990;
34
1227-1231
-
22
Gentry C A, Rodvold K A, Novak R M, Hershow R C, Naderer O J.
Retrospective evaluation of therapies for Staphylococcus aureus endocarditis.
Pharmacotherapy.
1997;
17
990-997
-
23
Siegman-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M.
The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia.
Scand J Infect Dis.
2005;
37
572-578
-
24
Stryjewski M E, Szczech L A, Benjamin Jr D K et al..
Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.
Clin Infect Dis.
2007;
44
190-196
-
25
Levine D P, Fromm B S, Reddy B R.
Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.
Ann Intern Med.
1991;
115
674-680
-
26
Markowitz N, Quinn E L, Saravolatz L D.
Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection.
Ann Intern Med.
1992;
117
390-398
-
27
Fowler Jr V G, Boucher H W, Corey R et al..
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
.
N Engl J Med.
2006;
355
653-665
-
28
Charles P G, Ward P B, Johnson P D, Howden B P, Grayson M L.
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus
.
Clin Infect Dis.
2004;
38
448-451
-
29
Khosrovaneh A, Riederer K, Saeed S et al..
Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis.
2004;
38
1328-1330
-
30
Sakoulas G, Moise-Broder P A, Schentag J, Forrest A, Moellering Jr R C, Eliopoulos G M.
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.
J Clin Microbiol.
2004;
42
2398-2402
-
31
Hidayat L K, Hsu D I, Quist R, Shriner K A, Wong-Beringer A.
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Arch Intern Med.
2006;
166
2138-2144
-
32
Baddour L M, Wilson W R, Bayer A S et al..
Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American Heart Association.
Circulation.
2005;
111
e394-e434
-
33
Korzeniowski O, Sande M A.
Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study.
Ann Intern Med.
1982;
97
496-503
-
34
Abrams B, Sklaver A, Hoffman T, Greenman R.
Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers.
Ann Intern Med.
1979;
90
789-791
-
35
Simon G L, Smith R H, Sande M A.
Emergence of rifampin-resistant strains of Staphylococcus aureus during combination therapy with vancomycin and rifampin: a report of two cases.
Rev Infect Dis.
1983;
5(Suppl 3)
S507-S508
-
36 NDA 21-572/Supplement 008 Cubicin® (daptomycin for injection): Sponsor's Background Package for Anti-Infective Drugs Advisory Committee Meeting Schedule for March 6, 2006. Report Number: NDA 21-572/S 008. Lexington, MA; Cubist Pharmaceuticals, Inc 2006: 1-92
-
37
Benvenuto M, Benziger D P, Yankelev S, Vigliani G.
Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.
Antimicrob Agents Chemother.
2006;
50
3245-3249
-
38
Cunha B A, Eisenstein L E, Hamid N S.
Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity.
Heart Lung.
2006;
35
207-211
-
39
Silverman J A, Mortin L I, Vanpraagh A D, Li T, Alder J.
Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.
J Infect Dis.
2005;
191
2149-2152
-
40
Stevens D L, Herr D, Lampiris H, Hunt J L, Batts D H, Hafkin B.
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Clin Infect Dis.
2002;
34
1481-1490
-
41
Howden B P, Ward P B, Charles P G et al..
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
Clin Infect Dis.
2004;
38
521-528
-
42
Ben Mansour E H, Jacob E, Monchi M et al..
Occurrence of MRSA endocarditis during linezolid treatment.
Eur J Clin Microbiol Infect Dis.
2003;
22
372-373
-
43
Ruiz M E, Guerrero I C, Tuazon C U.
Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid.
Clin Infect Dis.
2002;
35
1018-1020
-
44
Sperber S J, Levine J F, Gross P A.
Persistent MRSA bacteremia in a patient with low linezolid levels: correspondence.
Clin Infect Dis.
2003;
36
675-676
-
45
Shorr A F, Kunkel M J, Kollef M.
Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
J Antimicrob Chemother.
2005;
56
923-929
-
46 U.S. Food and Drug Administration (FDA). FDA Alert: Linezolid (market as Zyvox) Information. Available at: http://www.fda.gov/cder/drug/infopage/linezolid/default.htm Accessed May 12, 2007
-
47
Kaka A S, Rueda A M, Shelburne III S A, Hulten K, Hamill R J, Musher D M.
Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus
.
J Antimicrob Chemother.
2006;
58
680-683
-
48
Drew R H, Perfect J R, Srinath L, Kurkimilis E, Dowzicky M, Talbot G H.
Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group.
J Antimicrob Chemother.
2000;
46
775-784
-
49
Olsen K M, Rebuck J A, Rupp M E.
Arthralgias and myalgias related to quinupristin-dalfopristin administration.
Clin Infect Dis.
2001;
32
e83-e86
-
50
Watanakunakorn C.
Clindamycin therapy of Staphylococcus aureus endocarditis: clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin.
Am J Med.
1976;
60
419-425
-
51
Paterson D L.
Clinical experience with recently approved antibiotics.
Curr Opin Pharmacol.
2006;
6
486-490
Sara E CosgroveM.D. M.S.
Johns Hopkins Medical Institutions, Osler 425
600 N. Wolfe St., Baltimore, MD 21287
eMail: scosgro1@jhmi.edu
